A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorDizal Pharmaceuticals
About this trial
This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL.
This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.
Eligibility criteria
Qualifiers
Male and female ≥ 18 years of age.
ECOG performance status 0-2, and life expectancy ≥ 6 months.
Confirmed newly diagnosis or treatment naïve CLL/SLL with indication for treatment.
Patients with SLL must have at least one measurable lesion.
Disqualifiers
Any of previous or current treatment prohibited by protocol.
Any unresolved > grade 1 drug-related adverse events.
Known or suspected Richter's transformation, or prolymphocytic leukemia.
CNS involvement.
Trial design
Treatments tested in this trial
- DZD8586
- Venetoclax
Treatment groups
66 Participants
are divided into 1 treatment groupLocations
15Anhui Provincial Cancer Hospital230031, HefeiAnhui, China
Peking University Third Hospital100191, BeijingBeijing Municipality, China
Nanfang Hospital, Southern Medical University510515, GuangzhouGuangdong, China
Zhujiang Hospital of Southern Medical University510280, GuangzhouGuangdong, China
Sponsors and collaborators
Dizal Pharmaceuticals
Lead sponsor
Source ClinicalTrials.gov